Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia

ConditionSchizophrenia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorRWTH Aachen University

About this trial

In the last years, the imbalance between excitatory and inhibitory neuronal activity has come to the fore as a possible molecular disease mechanism of schizophrenia . Pharmacological studies have suggested different fMRI and EEG markers of that molecular dysfunction (resting state connectivity changes, auditory mismatch and steady state deficits). However, previous research is inconclusive regarding their genetic basis, their reliability, inter-individual relationship as well as disease specificity. Therefore, in this study we aim at estimating the effect sizes, test-retest-reliability and clinical correlates of the respective markers in a comparative fashion in patients with schizophrenia, their relatives and healthy control subject. To assess their molecular validity, we will assess their relationship with glutamatergic and GABAergic genotypes and cellular disease models. The proof of such a relation would give the opportunity of detecting a glutamatergic and GABAergic imbalance throughout non-invasive imaging. Furthermore, it would help deepening our understanding of the molecular pathophysiology of mental disorders which will be essential for the development of more effective drugs.

Eligibility criteria

Qualifiers

diagnosis of schizophrenia according to DSM-5

aged 18 to 80

being mentally and contractually capable to give their consent to study participation

Disqualifiers

pregnancy

structural neurological disease

a further psychiatric comorbidity that dominates in the clinical appearance

aged 18 to 80

Trial design

Treatments tested in this trial

  • Genotyping

Treatment groups

600 Participants
are divided into 3 treatment groups

Sponsors and collaborators